Source: http://www.patentgenius.com/patent/8623908.html
Timestamp: 2018-11-21 17:37:26
Document Index: 758313215

Matched Legal Cases: ['Application No. 2', 'Application No. 2606', 'Application No. 04801399', 'Application No. 2', 'Application No. 176333', 'Application No. 2004304716', 'Application No. 554380']

Use of tellurium compounds for inhibition of interleukin-converting enzyme - Patent # 8623908 - PatentGenius
8623908 Use of tellurium compounds for inhibition of interleukin-converting enzyme
Inventor: Albeck, et al.
U.S. Class: 514/450; 514/492
Field Of Search: ;514/450; ;514/492
International Class: A61K 31/335; A61K 31/28
Foreign Patent Documents: 4007473; 0583026; 1427415; 96/06618; 96/18392; 96/18401; 01/90070; 01/94351; 01/98325; 02/42278; 02/094263; 03/044038; 2004/002961; 2004/058718; 2005/060341; 2006/030437; 2006/030439; 2006/030440
Other References: Makarovsky et al., "Tellurium compound AS101 induces PC12 differentiation and rescues the neurons from apoptotic death", Annals of the NewYork Academy of Sciences, (2003), 1010 (Apoptosis), pp. 659-666. cited by examiner.
Montero et al., "AS-101: a modulator of in vitro T-cell proliferation". Anti-cancer Drugs, 4:351-354 (1993). cited by applicant.
Kozenitzky et al., "Immunomodulatory effects of AS101 on interleukin-2 production and T-lymphocyte function of lymphocytes treated with psoralens and ultraviolet A" Photodermatol Photoimmunol Photomed 9:24-28 (1992). cited by applicant.
Sredni et al., "The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody". Clin. exp. Immunol. 79, 443-447 (1990). cited by applicant.
Sredni et al., "The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent". Int J Immunopharmac., 14(4):613-619 (1992). cited by applicant.
Nyska et al., "Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: a potential drug for AIDS and cancer patients". Arch Toxicol, 63:386-393 (1989). cited by applicant.
Kalechman et al., "Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557" Cancer Research 51:5614-5620(1991). cited by applicant.
U.S. Appl. No. 60/610,660. cited by applicant.
Blank et al., The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody Clin. Exp. Immunol. 79, 443-447 (1990). cited by applicant.
Xu et al., "The Cytoprotective Effect of the Immunomodulator AS101 Against Hydrochloride Induced Gastric Lesions" Res. Com Mol. Path. Pharm 87(1) 4-20 (1995). cited by applicant.
Kalechman et al., "Delay in the Onset of Systemic Lupus Erythematosus Following Treatment With the lmmunomodulator AS101 Association With IL-10 Inhibition and Increase in TNF-alpha levels 1" J. Immunol. 159:2658-2667 (1997). cited by applicant.
Kalechman et al., "Production of the Novel Mesangial Autocrine Growth Factors GDNF and IL-10 Is Regulated by the Immunomodulator AS 101" J. Am. Soc. Nephrol. 14:620-630 (2003). cited by applicant.
Laurincova., "Interleukin-1 Family: From Genes to Human Disease" Acta. Univ. Palacki. Olomuc., Fac. Med. 143: 19-29 (2000). cited by applicant.
Vonsover et al., "Inhibition of the Reverse Transcriptase Activity and Replication of Human Immunodeficiency Virus Type 1 by AS 101 in Vitro" AIDS Res Hum Retroviruses. 8(5):613-23 (1992). cited by applicant.
Kim et al., "Regulation of Caspases by Nitric Oxide" Ann. N.Y. Acad. Sci. 962: 42-52 (2002). cited by applicant.
Rathmell et al., "The Central Effectors of Cell Death in the Immune System" Ann. Rev. Immunol. 17: 781-828 (1999). cited by applicant.
Ohta et al., "Expression of IL-18 in psoriasis" Arch. Dermatol. Res. 293: 334-342 (2001). cited by applicant.
Yamamura et al., Interferon-g--Inducing Activity of Interleukin-18 in the Joint With Rheumatoid Arthritis Arthritis Rheum. 44: 275-285 (2001). cited by applicant.
Kalechman et al., "Role of Endogenous Cytokines Secretion in Radioprotection Conferred by the Immunomodulator Ammonium Trichloro(dioxyethy1ene-0-0')tellurate" Blood 85: 1555 (1995). cited by applicant.
Dinarello., "Biologic basis for interleukin-1 in disease" Blood 87: 2095-2147 (1996). cited by applicant.
Kalechman et al., "Protective and Restorative Role of AS101 in Combination with Chemotherapy1" Cancer Res. 51: 1499-1503 (1991). cited by applicant.
Sredni et al., Ammonium Trichloro(dioxoethylene-o,o1) tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine LoopCancer Res. 64: 1843-1852 (2004). cited by applicant.
Mendoza et al., Inhibition of Cytokine-Induced Microvascular Arrest of Tumor Cells by Recombinant Endostatin Prevents Experimental Hepatic Melanoma MetastasisCancer Res. 64: 304-310 (2004). cited by applicant.
Yano et al., "Multifunctional interleukin-1.beta. promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules" Cancer Sci. 94: 244-252 (2003). cited by applicant.
Strassmann et al., "The Immunomodulator AS-101 Inhibits IL-10 Release and Augments TNFa and 1L-1a Release by Mouse and Human Mononuclear Phagocytes" Cell Immunol. 176(2):180-5 (1997). cited by applicant.
Hanna Rosenblatt-Bin et al., "The Immunomodulator AS101 Restores TH1 Type of Response Suppressed by Babesia rodhaini in BALB/c Mice" Cell. Immunol. 184: 12-25 (1998). cited by applicant.
Buettner et al., "Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention1" Clin. Cancer Res. 8: 945-954 (2002). cited by applicant.
Kalechman et al., "Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice" Exp. Hematol. 23(13):1358-66 (1995). cited by applicant.
Novick et al., "Interleukin-18 Binding Protein: A Novel Modulator of the Th1 Cytokine Response" Immunity 10: 127-136, (1999). cited by applicant.
Tsutsui et al., "Pathophysiological roles of interleukin-18 in inflammatory liver diseases" Immunol. Rev. 174: 192-209, (2000). cited by applicant.
Oppenheim et al., "There is more than one interleukin I" Immunol. Today 7: 45-56 (1986). cited by applicant.
Sredni et al., "Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin" Immunology 70(4):473-7 (1990). cited by applicant.
Kalechman et al., "Synergistic Anti-Tumoral Effect of Paclitaxel (TAXOL)+AS101 In A Murine Model of B16 Melanoma: Association With RAS-Dependent Signal-Transduction Pathways" In. J. Cancer 86: 281-288 (2000). cited by applicant.
Laichalk et al., "Tumor Necrosis Factor Mediates Lung Antibacterial Host Defense in Murine Klebsiella Pneumonialnfect" Immun. 64: 5211-5218 (1996). cited by applicant.
Albeck et al., "Tellurium Compounds: Selective Inhibition of Cysteine Proteases and Model Reaction with Thiols" Inorg. Chem. 37: 1704-1712 (1998). cited by applicant.
Giamila et al., "Interleukin-18 and interleukin-l[beta]: Two cytokine substrates for ICE (caspase-1)" J. Clin. Immunol. 19:1 (1999). cited by applicant.
Fischer et al., "Interleukin-1 Receptor Blockade Improves Survival and Hemodynamic Performance in Escherichia coli Septic Shock, but Fails to Alter Host Responses to Sublethal Endotoxemia" J. Clin. Invest. 89: 1551-1557 (1992). cited by applicant.
Singer et al., "Interleukin 1,8 Is Localized in the Cytoplasmic Ground Substance But Is Largely Absent From the Golgi Apparatus and Plasma Membranes of Stimulated Human Monocytes" J. Exp. Med. 167: 389-407 (1988). cited by applicant.
Kalechman et al., "Radioprotective Effects of the Immunomodular AS1011" J. Immunol. 145: 1512-1517 (1990). cited by applicant.
Echtenacher et al., "Requirement of Endogenous Recovery From Tumor Necrosis Factor/Cachectin for Experimental Peritonitis1" J. Immunol. 145: 3762-3766 (1990). cited by applicant.
Finbloom et al., "IL-10 Induces the Tyrosine Phophorylation of tyk2 and Jakl Complexes in Human T Cells and Monocytes" J. Immunol. 155: 1079-1090 (1995). cited by applicant.
Kalechman et al., "The Antitumoral Effect of the Immunomodulator AS101 and Paclitaxel (Taxol) in a Murine Model of Lung Adenocarcinoma" J. Immunol. 156: 1101-1109 (1996). cited by applicant.
Esfandiari et al., "A Proinflammatory Role of IL-18 in the Development of Spontaneous Autoimmune Disease1" J. Immunol. 167: 5338-5347 (2001). cited by applicant.
Kashiwamura et al., "Roles of Interleukin-18 in Tissue Destruction and Compensatory Reactions" J. Immunother. 25: S4-S11 (2002). cited by applicant.
Sredni et al., Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS 101J. Nat. Cancer Inst. 88: 1276-1284 (1996). cited by applicant.
Tanaka et al., "Mature Form of Interleukin 18 Is Expressed in Rheumatoid Arthritis Synovial Tissue and Contributes to Interferon-y Production by Synovial T Cells" J. Rheumatol. 28: 1779-1787 (2001). cited by applicant.
Sredni et al., "The Biological Activity and Immunotherapeutic Properties of AS-101, a Synthetic Organotellurium Compound" Nat. Immun. Cell Growth Regul. 7(3):163-8 (1988). cited by applicant.
Shani et al., "Immunologic Effects of AS101 in the Treatment of Cancer Patients" Nat. Immun. Cell Growth Regul. 9 (3):182-90 (1990). cited by applicant.
Sredni et al., " A New Immunomodulating compound (AS-101) with potential therapeutic application" Nature 330 (6144):173-6 (1987). cited by applicant.
Tracey et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" Nature 330: 662-664 (1987). cited by applicant.
Echtenacher et al., "Critical protective role of mast cells in a model of acute septic peritonitis" Nature 381: 75-77(1996). cited by applicant.
Ghayur et al., "Caspase-1 processes IFN- `Yinducing factor and regulates LPS-induced IFN-`Y production" Nature 386: 619-623 (1997). cited by applicant.
Niu et al., "Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis" Oncogene 21: 2000-2008 (2002). cited by applicant.
Wei et al., "Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasisOncogene" 22:319-329 (2003). cited by applicant.
Repovic et al., "Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells" Oncogene 22: 8117-8124 (2003). cited by applicant.
Rosenblatt-Bin et al., "Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxide" Parasite Immunol. 18: 297-306 (1996). cited by applicant.
Wong et al., "Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus" Rheumatol. 39: 1078-1081 (2000). cited by applicant.
Gu et al., "Activation of Interferon-y Inducing Factor Mediated by Interleukin-1B Converting Enzyme" Science 275: 206-209 (1997). cited by applicant.
Oberholzer et al., "Differential Effect of Caspase Inhibition on Proinflammatory Cytokine Release in Septic Patients" Shock 14: 253-258 (2000). cited by applicant.
Villavicencio et al., "Induced Nitric Oxide Inhibits IL-6-Induced STAT3 Activation and Type II Acute Phase Mana Expression" Shock 13: 441-445 (2000). cited by applicant.
Black et al. "Activation of Interleukin--1Beta by a Co-Induced Protease", FEBS Letters, 247(2): 386-390, 1989. cited by applicant.
Hara et al. "Inhibition of Interleukin 113 Converting Enzyme Family Proteases Reduces Ischemic and Excitotoxic Neuronal Damage", Proc. Natl. Acad. Sci. USA, 94: 2007-2012 (1997). cited by applicant.
Hardy "The Secret Life of the Hair Follicle", Trends in Genetics, 8(2): 41-78, 1992. cited by applicant.
Kalechman et al. "Up-Regulation by Ammonium Trichloro(Dioxoethylene-0,0') Tellurate (AS 101) of Fas/Apo-1 Expression on B16 Melanoma Cells: Implications for the Antitumor Effects of AS101", The Journal of Immunology, 161:3536-3542, 1998. cited byapplicant.
Sredni et al. "Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Treated With Carboplatin and Etoside", Journal of Clinical Oncology, 13(9): 2342-2353, 1995. cited by applicant.
Wieslander et al. "Antioxidative Properties ofOrganotellurium Compounds in Cell Systems", Biochemical Pharmacology, 55:573-584, 1998. cited by applicant.
Siderowf et al. "Update on Parkinson Disease", Annals of Internal Medicine, 138(8): 651-658, 2003. cited by applicant.
Sredni et al. "Hair Growth Induction by the Tellurium Immunomodulator AS 101: Association With Delayed Terminal Differentiation of follicular Keratinocytes and Ras-Dependent Up-Regulation of KGF Expression", The FASEB Journal, 18(2): 400-402,2004.cited by applicant.
Makarovsky et al. "Tellurium Compound AS 10 I Induces PC 12 Differentiation and Rescue the Neurons From Apoptotic Death", Annals of the New York Academy of Sciences, 1010: 659-666,2003. cited by applicant.
Kalechman et al. "Inhibition oflnt.about.rleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis", The Journal of Biological Chemistry, 279(23):24724-24732, 2004. cited byapplicant.
Kalechman et al. "Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS 101 in Protecting Mice From Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention", the Journal of Immunology, 169 (1): 384-392, 2002. cited byapplicant.
Sredni et al. "The Protective Role of the Immunomodulator AS101 Against Chemotherapy-Induced Alopecia Studies on Human and Animal Models", International Journal ofCancer, 65(1): 97-103, 1996. cited by applicant.
Sishi et al. "Defective Production of Interleukin-2 (IL-2) in Patients with Alopecia Areata", Chemical Abstracts, 108:519, 1988, Abstract. cited by applicant.
Shohat et al. "In Vitro Cytokine Profile in Childhood Alopecia Areata and the Immunomodulatory Effects of AS-101 ", Clinical and Experimental Dematology, 30(4): 432-434, 2005. cited by applicant.
Jimenez et al. "Interleukin I Protects From Cytosine Arabinoside-Induced Alopecia in the Rat Model", esearch Communications, the FASEB Journal, 5:2456-2458, 1991. cited by applicant.
Gross et al. "Tellurium Dioxide Suspension in the Treatment of Seborrhea Capitis", A.M.A. Archives of Dermatology, 78(1 ): 92-94, 1958. cited by applicant.
Shults "Treatments of Parkinson Disease. Circa 2003", Archives ofNeurology, 60: 1680-1684, Dec. 2003. cited by applicant.
Merck "Human Immunodeficiency Virus (HIV) Infection", Merck Manual Home Edition for Patients and Caregivers, 10 P., May 19, 2008. http://merck.com/mmhe/sec 17 /ch 199/ch 199a.html. cited by applicant.
Iupac "Acyl Groups", IUPAC Gold Book, 2 P., Nov. 27, 2007. http://goldbook.iupac.org/ A00 123 .html. cited by applicant.
Dumont "The Interleukin-1 Families ofCytokines and Receptors: Therapeutic Potential for Immunomodulation and the Treatment of Inflammatory Disorders", Expert Opinion in Therapeutic Patents, 16(7): 879-912, 2006. cited by applicant.
Delagarza "Pharmacologic Treatment of Alzheimer's Desease: An Update", American Family Physician, 68(7): 1365-1372, OJ Oct. 2003. cited by applicant.
Boettner et al. "the Role of Rho GTPase in Disease Development", Gene, 286: 155-174, 2002. cited by applicant.
Official Action Dated Aug. 26, 2008 From the Canadian Intellectual Property Office Re. Application No. 2,550,459. cited by applicant.
Official Action Dated Feb. 14, 2007 From the US Patent and Trademark Office Re. U.S. Appl No. 11/226,374. cited by applicant.
Official Action Dated Jan. 11, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/226,374. cited by applicant.
Official Action Dated Nov. 7, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/226,374. cited by applicant.
Office Action Dated 26 Jan. 2009 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/663,031. cited by applicant.
International Preliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re. Application No. PCT/IL2005/000992. cited by applicant.
International Preliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re. application No. PCT/IL2005/000990. cited by applicant.
International Prepliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re. Application No. PCT/IL2005/000989. cited by applicant.
International Preliminary Report on Patentability Dated Sep. 28, 2006 From the International Bureau of WIPO Re. Application No. PCT/IB2004/004163. cited by applicant.
International Preliminary Report on Patentability Dated Apr. 26, 2007 From the International Bureau of WIPO Re. Application No. PCT/IL2005/000991. cited by applicant.
Examination Report Dated Oct. 29, 2008 From the Government of India, Patent Office Re. Application No. 2606/CHENP/2006. cited by applicant.
Communication Pursuant to Rules 109 and 110 EPC Dated Nov. 20, 2006 From the European Patent Office Re. Application No. 04801399.9. cited by applicant.
Shults "Treatments of Parkinson Disease. Circa 2003", Archives of Neurology, 60: 1680-1684, Dec. 2003. cited by applicant.
Merck "Human Immunodeficiency Virus (HIV) Infection", Merck Manual Home Edition for Patients and Caregivers, 10 P., May 19, 2008. http://merck.com/mmhe/sec 17/ch 199/ch 199a.html. cited by applicant.
Dumont "The Interleukin-1 Families of Cytokines and Receptors: Therapeutic Potential for Immunomodulation and the Treatment of Inflammatory Disorders", Expert Opinion in Therapeutic Patents, 16(7): 879-912, 2006. cited by applicant.
Delagarza "Pharmacologic Treatment of Alzheimer's Desease: An Update", American Family Physician, 68(7): 1365-1372,01 Oct. 2003. cited by applicant.
Response Dated Apr. 7, 2009 to Official Action of Nov. 7, 2008 From the US Patent and Trademark Office Re: U.S. Appl. No. 11/226,374. cited by applicant.
Official Action Dated Aug. 26, 2008 From the Canadian Intellectual Property Office Re.: Application No. 2,550,459. cited by applicant.
Official Action Dated Jun. 18, 2009 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/663,032. cited by applicant.
Official Action Dated Feb. 14, 2007 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/226,374. cited by applicant.
Office Action Dated Jan. 26, 2009 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/663,031. cited by applicant.
Office Action Dated Jun. 5, 2008 From the Israeli Patent Office Re. Application No. 176333. cited by applicant.
Examiner's Report Dated Apr. 15, 2009 From the Australian Government, IP Australia Re. Application No. 2004304716. cited by applicant.
Examination Report Dated May 14, 2009 From the Intellectual Property Office of New Zealand Re. Application No. 554380. cited by applicant.
Official Action Dated May 24, 2007 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/226,374. cited by applicant.
Abstract: Use of tellurium-containing compounds for treating conditions in which inhibition of caspase-1/interleuFkin-1.beta. enzyme (ICE) is beneficial is disclosed.
1. A method of treating a condition in which inhibition of interleukin-1.beta.-converting enzyme is beneficial, the method comprising administering to a subject in needthereof a therapeutically effective amount of at least one tellurium-containing compound selected from the group consisting of tellurium dioxide (TeO.sub.2), a complex of TeO.sub.2, a compound having general Formula I: ##STR00011## a compound havinggeneral Formula II: ##STR00012## and a compound having general Formula III: ##STR00013## wherein: each of t, u and v is independently 0 or 1; Y is selected from the group consisting of ammonium, phosphonium, potassium, sodium and lithium; X is ahalogen atom; and each of R.sub.1-R.sub.14 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl,carboxyalkyl, acyl, amide, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido, and thecondition in which inhibition of interleukin-1.beta.-converting enzyme is beneficial is selected from the group consisting of an excess dietary alcohol intake disease, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adultrespiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, scleroderma, chronic thyroiditis, Grave's disease, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatorybowel disease, Crohn's disease, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemia or a related disorder, myelodysplastic syndrome, multiple myeloma-related bonedisorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, a burn, Shigellosis, Huntington's disease, Kennedy's disease, prion disease, cerebralischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis,HIV-related encephalitis, aging, neurological damage due to stroke, ulcerative colitis, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, renal disease, polycystic kidney disease, HIV infection, tuberculosis, anyof various forms of cancer, organ failure, and meningitis.
2. The method of claim 1, wherein said tellurium-containing compound has said general Formula I.
3. The method of claim 2, wherein t, u and v are each 0.
4. The method of claim 3, wherein each of R.sub.1, R.sub.8, R.sub.9 and R.sub.10 is hydrogen.
5. The method of claim 4, wherein X is a halogen atom.
6. The method of claim 5, wherein X is chloro.
7. The method of claim 6, wherein Y is ammonium.
8. The method of claim 1, wherein said tellurium-containing compound is ammonium trichloro(dioxyethylene-O,O')tellurate.
9. The method of claim 1, wherein said condition is selected from the group consisting of an excess dietary alcohol intake disease, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome,glomerulonephritis, rheumatoid arthritis, scleroderma, chronic thyroiditis, Grave's disease, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease,atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, haemorrhagic shock, sepsis, septic shock, a burn, Shigellosis, myocardial ischemia, acute and chronic heart disease,myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, multiple sclerosis, HIV-related encephalitis, aging, ulcerative colitis, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japaneseencephalitis, renal disease, polycystic kidney disease, HIV infection, tuberculosis, organ failure, and meningitis.
10. The method of claim 1, wherein said therapeutically effective amount ranges from about 0.01 mg/m.sup.2/day to about 20 mg/m.sup.2/day.
11. The method of claim 1, wherein said at least one tellurium-containing compound forms a part of a pharmaceutical composition, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
12. The method of claim 11, wherein the concentration of said at least one tellurium-containing compound ranges from about 0.01 weight percent to about 50 weight percent of the total weight of said composition.
13. The method of claim 12, wherein the concentration of said at least one tellurium-containing compound ranges from about 0.1 weight percent to about 25 weight percent of the total weight of said composition.
14. The method of claim 11, wherein said pharmaceutical composition further comprises at least one additional active agent, the at least one additional active agent comprising one or more of an antibiotic agent. an antimicrobial agent, anantibacterial agent, an antifungal agent, an antiviral agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoal agent, an antioxidant, an antineoplastic agent, animmunomodulator, an interferon, an antidepressant, an antihistamine, a vitamin, and a hormone.
15. The method of claim 9, wherein said tellurium-containing compound is ammonium trichloro(dioxyethylene-O,O')tellurate.
16. The method of claim 9, wherein said condition is selected from the group consisting of haemorrhagic shock, sepsis, septic shock, a burn, Shigellosis, myocardial ischemia, acute or chronic heart disease, myocardial infarction, congestiveheart failure, atherosclerosis, coronary artery bypass graft, multiple sclerosis, HIV-related encephalitis, aging, ulcerative colitis, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, and polycystic kidneydisease.
17. The method of claim 16, wherein said tellurium-containing compound is ammonium trichloro(dioxyethylene-O,O')tellurate.
18. The method of claim 16, wherein said condition is selected from the group consisting of haemorrhagic shock, sepsis, septic shock, a burn, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure,atherosclerosis, coronary artery bypass graft, multiple sclerosis, aging, renal disease, and polycystic kidney disease.
19. The method of claim 18, wherein said tellurium-containing compound is ammonium trichloro(dioxyethylene-O,O')tellurate.
20. The method of claim 18, wherein said condition is selected from the group consisting of sepsis and septic shock.
21. The method of claim 20, wherein said tellurium-containing compound is ammonium trichloro(dioxyethylene-O,O')tellurate.
Chrominance signal processing circuit in color television receiver
Vehicle wheel assembly with a mechanism compensating for a varying wheel radius